ClinicalTrials.gg
CompletedNCT01162863Updated Jan 27, 2017Results posted

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

An interventional study of Lubiprostone and Placebo in Irritable Bowel Syndrome and Constipation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by University of Michigan · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Irritable bowel syndrome (IBS) is a common disorder which presents with abdominal pain or discomfort in association with altered bowel habit. IBS is further subcategorized as three types according to the predominant bowel movement pattern: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed-IBS (IBS-M). The exact causes of IBS remain incompletely understood, but proposed mechanisms include abnormal motility, visceral hypersensitivity, abnormal brain-gut interactions, psychological distress, and altered GI tract motility.

Lubiprostone, a novel drug that works by activating the colonic Chloride channel type 2(ClC-2), has been approved for use in patients with chronic idiopathic constipation and recently approved for the treatment of IBS-C in women aged 18 and older. By activating the ClC-2 chloride channel in the colon, lubiprostone allows more fluid secretion into the intestinal lumen which leads to softer stool consistency. In phase III clinical trials, patients with IBS-C receiving lubiprostone have reported improvements in many symptoms such as abdominal pain and constipation. However, there is limited physiologic data to explain how exactly lubiprostone improves IBS-C symptoms.

The Smartpill is a novel non-digestible capsule that is capable of measuring intraluminal pH, pressure, and temperature in the gastrointestinal (GI) tract. Smartpill has been shown to accurately measure whole gut as well as regional (i.e. stomach, small bowel, colon) transit time.

The primary aim of this study is to determine the effects of lubiprostone on whole GI tract transit, colonic transit, motility, and intraluminal pH in patients with IBS-C through evaluation with the Smartpill. The investigators propose to study the effect of lubiprostone vs. placebo on these parameters, and secondarily to evaluate changes in these parameters with differing doses of lubiprostone.

The investigators hypothesize that lubiprostone will increase whole GI and colonic transit compared to placebo in patient with IBS. the investigators do not expect a change in intraluminal pH with lubiprostone compared to placebo.

02

Conditions studied

  • Irritable Bowel Syndrome
  • Constipation

Keywords

  • IBSC
  • irritable bowel syndrome
  • constipation
03

In context

Irritable Bowel Syndrome

1,084 studies on the registry are indexed under Irritable Bowel Syndrome; 196 are open to participants now.

This study's enrollment of 60 is below the median of 70 across 869 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,503 studies on the registry; 189 are open to participants now.

Of its 167 completed or terminated interventional studies of FDA-regulated products, 132 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females >18 years of age
  • Meet Rome III criteria for IBS[2]:

    • Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following:

      1. Improvement with defecation
      2. Onset associated with a change in frequency
      3. Onset associated with a change in form (appearance) of stool
    • *Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
  • Fulfill the Rome III stool consistency criteria for IBS-C[2]

    • Hard or lumpy stools for >25% of bowel movements
    • Loose (mushy) or watery stools for \<25% of bowel movements
  • Capable of independently completing all requirements of the study including returning for required visits
  • Able to provide written informed consent for study participation
  • Willing to discontinue prohibited medications during study participation
  • Documentation of a normal colonoscopy within last 5 years if over age 50 years (or sigmoidoscopy if less than age 50)
  • Documentation of normal thyroid stimulating hormone(TSH) level, complet blood count (CBC) and electrolyte panel within prior 3 years
  • Females of childbearing potential must have a negative urine or serum pregnancy test at screening
  • Females of childbearing potential must use an effective means of contraception during the course of the study

    • Hormonal (oral, injectable, implantable, cervical/vaginal rings or patches)
    • Double-barrier (condoms and/or diaphragm with spermicides) or intrauterine devices provided under the care of a health care professional
    • Abstinence, in this case documentation of counseling will be recorded

Exclusion criteria

Exclusion Criteria:

  • Unable to understand or provide written informed consent
  • Pregnant or nursing
  • Patients with IBS-D, IBS-M or unsubtyped IBS by Rome III criteria[2]
  • IBS with diarrhea (IBS-D)

    1. Loose (mushy) or watery stools for >25% of bowel movements
    2. Hard or lumpy stools for \<25% of bowel movements
  • Mixed IBS (IBS-M)

    1. Hard or lumpy stools >25% of bowel movements
    2. Loose (mushy) or watery stools for >25% of bowel movements
  • Unsubtyped IBS

    1. Insufficient abnormality of stool pattern to meet criteria for IBS-C, IBS-D or IBS-M

  • Documented allergy or intolerance to lubiprostone
  • Failure of balloon expulsion test

    • Inability to expel 50cc balloon within 1 minute
  • Use of drugs known to affect gastrointestinal motility

    1. Laxatives (stable doses of fiber taken for minimum of 4 weeks will be allowed)

      Osmotic laxatives:

      Magnesium hydroxide, Polyethylene glycol,Lactulose, Sorbitol

      Stimulant laxatives:

      Bisacodyl, Anthraquinones (senna), Misoprostol

    2. Prokinetic agents:

      Metoclopramide, domperidone, erythromycin

    3. Anti-diarrheal agents:

      Loperamide, Diphenoxylate, Bismuth

    4. Anti-spasmotics:

      Dicyclomine, Hyoscyamine

    5. Opioid, narcotic, opioid/narcotic-containing analgesics:

      Morphine, Hydrocodone, Codeine, Methadone, Propoxyphene

    6. Probiotics
    7. Systemic antibiotics within last 3 months
    8. Recently initiated antidepressants (stable dose for >2 months for non-GI conditions will be allowed)
    9. Benzodiazepines * Subjects taking prohibited medications will be required to stop these at the screening visit and remain off of them until completion of the study.
  • Initiation of dietary changes potentially altering bowel transit within 4 weeks
  • Comorbid medical problems that may affect gastrointestinal transit or motility

    1. Previous surgery involving the stomach, small bowel or colon (prior appendectomy, cholecystectomy, polypectomy allowed)
    2. Previous history of small bowel obstruction for any reason
    3. History of any gastrointestinal malignancy
    4. History of dyssynergic defecation
    5. Unexplained nausea and vomiting
    6. History of inflammatory bowel disease (Crohn's or ulcerative colitis)
    7. History of microscopic colitis (lymphocytic or collagenous colitis)
    8. History of Hirschsprung's disease
    9. Severe or complicated diverticular disease
    10. Chronic pancreatitis
    11. History of celiac disease
    12. History of eating disorders (anorexia nervosa or bulimia)
    13. Cirrhosis
    14. Chronic hepatitis B or C infection
    15. HIV infection
    16. Diabetes
    17. Systemic sclerosis (scleroderma)
    18. Amyloidosis
    19. Untreated thyroid disease
    20. Chronic pulmonary disease
    21. Severe renal insufficiency or renal failure
    22. Current or recent history (within last 6 months) of:

      Diverticulitis, Duodenal or gastric ulcer, Acute pancreatitis, Ileus

  • Contraindications to SmartPill® (in addition to above):

Cardiac pacemaker, defibrillator, or other implanted electromagnetic device, Known Zenker's diverticulum, Dysphagia

05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Lubiprostone 8 mcg BID

    Drug: Lubiprostone · Other: Smartpill wireless motility capsule

  • Active comparator
    Lubiprostone 24 mcg QD

    Drug: Lubiprostone · Other: Smartpill wireless motility capsule

  • Placebo comparator
    Placebo

    Drug: Placebo · Other: Smartpill wireless motility capsule

Interventions

  • lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days

  • DrugPlacebo

    taken orally for 28 days

  • OtherSmartpill wireless motility capsule

    Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus

06

What researchers measure

Primary outcomes

  1. Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline

    Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm

    Time frame: 21-28 days

Secondary outcomes

  1. Change in Small Bowel pH and Colon pH From Baseline

    Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.

    Time frame: 21-28 days

  2. Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index

    Change in the motility index defined as the natural log \[(sum of pressure amplitudes times the number of contractions) + 1\] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.

    Time frame: 21-28 days

07

Results

Posted Jan 27, 2017
Limitations and caveats
This was a small study with wide variability among participants, so data should be interpreted with great caution.

Participant flow

Participant flow — Overall Study
MilestonePlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
Started181717
Completed171617
Not completed110
Withdrew: Lack of efficacy100
Withdrew: Adverse event010

Outcome measures

PrimaryChange in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline

Change in gastric emptying time, small bowel transit time, colon transit time and whole gut transit time measured in hours based on a measurement done at baseline and then again at 3 weeks into the intervention within each treatment arm

Time frame:
21-28 days
Reported as:
Mean · hours
Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline
hoursPlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
Gastric emptying time5.49 ± 13.776.52 ± 15.33-0.16 ± 3.17
Small bowel transit time0.2 ± 2.040.15 ± 1.78-0.001 ± 2.68
Colon transit time5.75 ± 21.23-4.43 ± 44.62.59 ± 31.15
Whole gut transit time10.32 ± 27.3-1.74 ± 42.671.67 ± 29.73
SecondaryChange in Small Bowel pH and Colon pH From Baseline

Change in the mean pH of the small intestine and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.

Time frame:
21-28 days
Reported as:
Mean · pH
Change in Small Bowel pH and Colon pH From Baseline
pHPlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
Small bowel pH0.18 ± 0.370.23 ± 0.360.24 ± 0.4
Colon pH-0.03 ± 0.50-0.07 ± 0.450.27 ± 0.56
SecondaryChange in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index

Change in the motility index defined as the natural log \[(sum of pressure amplitudes times the number of contractions) + 1\] for the small bowel and colon based on a measurement done at baseline and then again at 3 weeks into the intervention.

Time frame:
21-28 days
Reported as:
Mean · units on a scale
Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index
units on a scalePlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
Small bowel motility index0.06 ± 1.37-0.01 ± 1.890.6 ± 2.36
Colon motility index-0.34 ± 1.96-1.32 ± 1.970.17 ± 1.72

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/18 (11.1%)9/18 (50%)
Lubiprostone 24 mcg QD—0/17 (0%)11/17 (64.7%)
Lubiprostone 8 mcg BID—0/17 (0%)10/17 (58.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
DehydrationCardiac disorders1/180/170/17
Atrial fibrillationCardiac disorders1/180/170/17
Most frequent other events
Most frequent other events
EventPlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BID
DiarrheaGastrointestinal disorders2/186/174/16
NauseaGastrointestinal disorders4/186/176/17
FlatulenceGastrointestinal disorders4/182/174/17
Abdominal painGastrointestinal disorders2/184/172/17
Abdominal distentionGastrointestinal disorders0/182/174/17
VomitingGastrointestinal disorders0/183/170/17
HeadacheGeneral disorders1/182/172/17
Chest discomfortRespiratory, thoracic and mediastinal disorders0/180/171/17
DizzinessNervous system disorders1/181/171/17
Respiratory infectionRespiratory, thoracic and mediastinal disorders1/180/171/17

Baseline characteristics

The baseline data is given for those persons who actually completed the study, so the two people who dropped out were not included in the baseline measures. We determined this to be the more useful way to identify the effects of the three randomized procedures. Therefore the baseline data is based on the 50 participants who completed the study.

Age, Customized
Age, Customized(years)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
mean age39.9 ± 16.146.5 ± 18.737.2 ± 15.841.2 ± 17.2
Gender
Gender(Participants)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Female16151344
Male1146
Region of Enrollment
Region of Enrollment(participants)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
United States17161750
Baseline gastric emptying time
Baseline gastric emptying time(hours)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Mean4.25 ± 5.523.18 ± 0.954.67 ± 3.474.01 ± 3.74
Baseline Small Bowel Transit time
Baseline Small Bowel Transit time(hours)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Mean4.84 ± 1.694.01 ± 1.024.81 ± 2.134.63 ± 1.75
Baseline Colon Transit Time
Baseline Colon Transit Time(hours)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Mean32.18 ± 16.4644.61 ± 27.1837.12 ± 30.0438.15 ± 25.31
Baseline Whole Gut Transit Time
Baseline Whole Gut Transit Time(hours)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Mean41.47 ± 16.2651.81 ± 26.7847.0 ± 30.047.0 ± 24.97
Baseline Small Bowel pH
Baseline Small Bowel pH(units on pH scale)PlaceboLubiprostone 24 mcg QDLubiprostone 8 mcg BIDTotal
Mean6.82 ± 0.286.75 ± 0.346.77 ± 0.396.78 ± 0.33

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Michigan Health System
    Ann Arbor, Michigan 48103, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01162863
Collaborators
Takeda Pharmaceuticals North America, Inc.
Responsible party
Richard J. Saad, M.D. (Assistant Professor of Medicine, University of Michigan) — Principal investigator
First posted
Jul 15, 2010
Start date
Nov 2010
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Jan 27, 2017
Last update
Jan 27, 2017

Study contacts

Richard Saad
principal investigator · University of Michigan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lubiprostone

Start the discussion